The PNC Financial Services Group Inc. (PNC) topped market estimates on revenues and earnings for the third quarter of 2018. Despite the beat, the stock was down 1% in premarket trade, hurt by higher expenses.
The financial services firm reported total revenues of $4.3 billion, up 6% compared to the same period last year. Net income attributable to diluted common shares was $1.31 billion or $2.82 per diluted share compared to $1 billion or $2.16 per diluted share in the same period last year.
Net interest income grew 5% while non-interest income grew 6% during the quarter compared to the prior year period. Higher loan and securities yields and balances were partially offset by higher deposit and borrowing costs, reflecting interest rate hike impacts.
Net interest margin increased to 2.99% from 2.91% last year. Asset management revenue grew $65 million, reflecting benefits from the lower federal statutory income tax rate on BlackRock earnings and higher equity markets.
Non-interest expense rose 6% from the same period last year due to ongoing business investments as well as higher variable compensation related to revenue growth, increased staffing, higher retail banking compensation and higher marketing expense.
Average total assets were $377.9 billion in the third quarter. Average loans grew 2% to $223.3 billion while average deposits grew 1% to $262.5 billion. Total loans grew 1% and total deposits grew 2% from the prior-year period. Non-performing loans and assets declined by 10% and 12% respectively.
PNC posted earnings increases across all its business segments during the quarter. The company returned $0.9 billion of capital to shareholders in the third quarter through repurchases of $0.5 billion and dividends of $0.4 billion.
On October 4, the board declared a quarterly cash dividend of $0.95 per common share, payable on November 5, 2018.
PNC’s stock is down 8.7% so far this year and over the past one month, it has dropped 8.1%.
Most Popular
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.
Nike (NKE) bets on innovation and partnerships to return to high growth
Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company
Walgreens Boots Alliance set to report earnings next week. Here’s what to expect
Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the drug store chain that is expanding into a diversified healthcare provider, is on a restructuring drive aimed at better aligning the business with